Sanofi launches its $3.68 billion offer for Principia Biopharma

PARIS (Reuters) – Sanofi announced Friday the launch of its tender offer to acquire Principia Biopharma, a U.S. biotech company specializing in the development of treatments for autoimmune and allergic diseases, which will strengthen its portfolio in immunology.

The transaction, through a repurchase of all outstanding shares at a price of $100 per share, represents a cash transaction valued at approximately $3.68 billion ('3.1 billion) and is expected to close in the fourth quarter of 2020.

The offer, which closed on August 16, will expire on September 25.

Claude Chendjou

Share on
Facebook
Twitter
LinkedIn
Pinterest

Leave a Reply

Your email address will not be published.

Sanofi launches its $3.68 billion offer for Principia Biopharma


PARIS (Reuters) - Sanofi announced Friday the launch of its tender offer to acquire Principia Biopharma, a U.S. biotech company specializing in the development of treatments for autoimmune and allergic diseases, which will strengthen its portfolio in immunology.


The transaction, through a repurchase of all outstanding shares at a price of $100 per share, represents a cash transaction valued at approximately $3.68 billion ('3.1 billion) and is expected to close in the fourth quarter of 2020.


The offer, which closed on August 16, will expire on September 25.


Claude Chendjou

Facebook
Twitter
LinkedIn
Pinterest

Leave a Reply

Your email address will not be published.